CompuCyte and Genetics Institute to develop theranostics:
This article was originally published in Clinica
CompuCyte and Genetics Institute (GI) are to collaborate on developing diagnostic tests that help select patients for drug therapy and follow them during treatment - so-called theranostics. Under the agreement, CompuCyte will develop cell-based assays for monitoring the effects of drugs known as cell adhesion inhibitors. GI, a unit of American Home Products' pharmaceutical division Wyeth-Ayerst Laboratories, is developing cell adhesion inhibitors to treat vascular and inflammatory diseases. The assays will be performed with Compuctye's OneCyte laser scanning technology.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.